On Tuesday, the FDA approvedEli Lilly and Co's(NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
Once-monthly, Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.
Also Read: Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead...
Login or create a forever free account to read this news
Sign up/Log in